AB-101 Study

Study to Investigate the Effect of AB-101 in Breast Cancer Survivors

Approximately 80% of breast cancer survivors will suffer from a permanent reduction in nipple sensitivity and associated decrease in sexual quality of life. Currently, there are no treatments for restoring nipple sensitivity to improve sexual quality of life. It would thus be of great clinical benefit to post breast surgery patients if a safe and effective topical treatment for this condition can be developed.

We are currently screening participants for this study that is taking place in Newport Beach, California.

To See the Advertisement: Click Here
Interested Participants: Click Here
Read Study Details at: ClinicalTrials.gov
AB-103 Study 1

The Effect of AB-103 on Follicular Suflotrasnferase Activity in Female Pattern Hair Loss Patients

Topical minoxidil is the only US FDA approved topical drug for the treatment of androgenetic alopecia. Unfortunately, the clinical response to topical minoxidil remains low i.e., 30%-40%. In our previous work, we have demonstrated that the enzymatic activity of the sulfotransferase enzymes in hair follicles predicts minoxidil response. Subsequently, in an attempt to increase follicular sulfotransferase activity, we have developed a topical formulation - AB-103. The aim of the study is to evaluate the efficacy of AB-103 in increasing the minoxidil sulfotrasnferase enzyme activity in human hair follicles in-vivo.

AB-103 Study 2

Minoxidil Adjuvant Therapy in Female Pattern Hair Loss Patients Study

Topical minoxidil is the only US FDA approved topical drug for the treatment of androgenetic alopecia. Unfortunately, the clinical response to topical minoxidil remains low i.e., 30%-40%. In our previous work, we have demonstrated that the enzymatic activity of the sulfotransferase enzymes in hair follicles predicts minoxidil response. Subsequently, in an attempt to increase follicular sulfotransferase activity, we have developed a topical formulation - AB-103. The aim of the study is to evaluate the efficacy of AB-103 as an adjuvant therapy to 5% topical minoxidil foam in the treatment of FPHL. This is a head-to-head prospective clinical study.

AB-105 Study

The Effect of AB-105 as a Prophylactic Treatment Against the Development of Ponytail Alopecia

Frontal hair loss is a frequent feature in female patients who wear their hair in a ponytail. In a recent study, 79% of women presenting with frontal hair loss reported wearing their hair in a ponytail four or more days per week for an average period of 10 years. Frontal hair loss is a subset of traction alopecia, hair loss that occurs after persistent pulling on the roots of hair over time. Each hair follicle in the scalp contains an arrector pili muscle that, when contracted, erects the hair. Previously we have demonstrated that stimulating contraction of the arrector pili muscle can increase the threshold of the force required to pull hairs by as much as 400%. The aim of the study is to evaluate the efficacy of AB-105 formulated as a novel facial cream that when applied to the forehead, near the hairline, can increase the force required to pull hairs; thus, reducing the risk of developing ponytail alopecia.

AB-106 Study

A Study of AB-106 for the Reduction of Post Transplant Surgery Shock Hair Loss

Shock hair loss is experienced by the majority of patients following hair transplant surgery. Surgically grafting and implanting hair follicles negatively impacts the survival of hair follicles and induces early entry into telogen phase. AB-106 is a novel kit for use during transplant surgery that reduces the negative impact of surgically grafting hair follicles.